Cargando…
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very difficult to treat due to the lack of an effective targeted therapy. However, recent advances in the molecular characterization o...
Autores principales: | Masci, Domiziana, Naro, Chiara, Puxeddu, Michela, Urbani, Andrea, Sette, Claudio, La Regina, Giuseppe, Silvestri, Romano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672974/ https://www.ncbi.nlm.nih.gov/pubmed/38005235 http://dx.doi.org/10.3390/molecules28227513 |
Ejemplares similares
-
Emerging Direct Targeting β-Catenin Agents
por: Nalli, Marianna, et al.
Publicado: (2022) -
Induction of Ferroptosis
in Glioblastoma and Ovarian
Cancers by a New Pyrrole Tubulin Assembly Inhibitor
por: Puxeddu, Michela, et al.
Publicado: (2022) -
Emerging Therapeutic Agents for Colorectal Cancer
por: Nalli, Marianna, et al.
Publicado: (2021) -
Anticancer Activity of (S)-5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyridin-4-ylmethyl)amino)propan-2-yl)-1H-indole-2-carboxamide (RS4690), a New Dishevelled 1 Inhibitor
por: Coluccia, Antonio, et al.
Publicado: (2022) -
The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells
por: Naro, Chiara, et al.
Publicado: (2021)